Printer Friendly

NEORX FILES ONCOTRAC COMPARISON STUDY WITH FDA AND RECEIVES $3.6 MILLION MILESTONE FROM BOEHRINGER INGELHEIM

 SEATTLE, Sept. 30 /PRNewswire/ -- NeoRx Corporation (NASDAQ: NERX) today announced that it has filed with the FDA data demonstrating that the OncoTrac(R) product produced by Dr. Karl Thomae GmbH ("Thomae"), a wholly owned subsidiary of the Boehringer Ingelheim group (BI), is the same as the product described in NeoRx's previously filed Product License Application for its OncoTrac small cell lung cancer imaging kit.
 This FDA filing resulted in a $3.6 million milestone payment from BI to purchase an additional 937,500 shares of unregistered NeoRx common stock at a per share price of $3.84. Of the $3.6 million proceeds, which were received Sept. 29, 1993, $1.3 million is attributable to the purchase of stock and the remaining $2.3 million is license fee revenue to be recorded in the quarter ending Sept. 30, 1993.
 "Although BI must still file with the FDA its own manufacturing license applications, expected by year end, this completes NeoRx's studies to qualify Thomae as the manufacturer of the OncoTrac SCLC imaging kit," said Paul G. Abrams, M.D., J.D., NeoRx's president and CEO. "Previously, the FDA had asked for extensive biochemical and preclinical animal data to demonstrate the equivalence of the product produced by BI with that of the product made by a former manufacturer and tested by NeoRx in a Phase III trial. The FDA had also requested a small clinical trial to demonstrate that the BI product behaves similarly in patients. We believe that the data submitted support qualifying Thomae as the manufacturer of this product," continued Abrams.
 OncoTrac small cell lung cancer imaging kit determines the stage of the disease, i.e., how far the tumor had spread, with a single test that is simple and safe. The data from NeoRx's Phase III clinical trial showed that OncoTrac is the best single test to determine the stage of the cancer, and is as accurate in identifying extensive disease as is a combination of four standard tests. NeoRx announced previously that it had received a letter from the FDA indicating that there are no issues regarding the clinical utility of the product.
 "We believe that review of the comparison data submitted by NeoRx, and the manufacturing information to be submitted by BI, are the only hurdles remaining prior to the inspection of the Thomae facility in conjunction with product approval," said Dr. Abrams. "The Phase III data indicate that the product is safe, effective and should be very cost-efficient."
 BI is continuing to widen its research activities in the field of biotechnology in addition to its comprehensive basic research in its traditional areas. The commitment to OncoTrac reflects BI's intention to step up its growing involvement in the hospital business.
 NeoRx Corporation develops targeted biopharmaceutical products that detect and treat human illnesses with a primary focus on cancer. The company has three cancer therapy trials in progress, has filed for marketing approval with the FDA its OncoTrac Small Cell Lung Cancer Imaging Product and has completed a Phase III trial for a non-small cell lung cancer imaging agent. Targeted biopharmaceuticals to treat cancer and restenosis after angioplasty are in preclinical testing.
 -0- 9/30/93
 /CONTACT: Robert M. Littauer, senior VP, CFO of NeoRx, 206-286-2519, or Bonnie K. Sterling of Noonan/Russo, 212-696-4455/
 (NERX)


CO: NeoRx Corporation ST: Washington IN: MTC SU:

LG-SH -- NY014 -- 7123 09/30/93 08:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 30, 1993
Words:564
Previous Article:IMMUNOGEN RECEIVES U.S. PATENT ON ITS CYTOTOXIC AGENT, BLOCKED RICIN, AND ITS USE IN CANCER THERAPEUTICS
Next Article:CHEMICAL WASTE MANAGEMENT CHARGE TO REDUCE WMX TECHNOLOGIES THIRD QUARTER NET INCOME $285.3 MILLION, OR $.59 PER SHARE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters